{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-048471","form_type":"8-K","ticker":"INGN","cik":"0001294133","company_name":"Inogen Inc","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.501931+00:00","generated_at":"2026-06-10T14:32:27.664555+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inogen completes acquisition of Physio-Assist for ~$32M cash plus up to $13M earnout","bullets":["Paid ~$32M cash at closing, subject to net debt adjustment; potential earnout up to $13M if FDA clearance within 4 years.","Physio-Assist's Simeox airway clearance device targets bronchiectasis; 400k-490k US patient population.","Simeox CE-marked, sold in Europe/Asia/Middle East; Inogen to pursue FDA submission.","Expected immaterial to 2023 revenue, immediately accretive to gross margin, accretive to adjusted earnings by 2027.","Recurring revenue from disposables in addition to capital sales per device."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-048471","json":"https://secwatch.observer/filing/0000950170-23-048471.json","markdown":"https://secwatch.observer/filing/0000950170-23-048471.md","text":"https://secwatch.observer/filing/0000950170-23-048471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1294133/000095017023048471/0000950170-23-048471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1294133/000095017023048471/ingn-20230914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:32:27.664555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20b38c46fdadba583639e4e9b438256a3b07ce2a","claim":"Inogen Inc completed an acquisition involving Physio-Assist SAS for approximately $32,000,000 cash at closing subject to adjustment for the estimated net debt amount (closed 2023-09-14).","evidence_excerpt":"clearance technique) for patients suffering from obstructive respiratory diseases. Pursuant to the terms of the Share Purchase Agreement, Inogen paid the Sellers approximately $32,000,000 cash at closing subject to adjustment for the estimated net debt amount of Physio-Assist SAS (subject to potential adjustment after closing following confirmation of the actual","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017023048471/0000950170-23-048471-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Physio-Assist SAS"},{"label":"Consideration","value":"approximately $32,000,000 cash at closing subject to adjustment for the estimated net debt amount"},{"label":"Closing","value":"2023-09-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}